Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

NCT03744910 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT03744910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03744910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Terminated
Start date
October 14, 2019
Completion date
April 8, 2024
Enrollment
194 (actual)
Sites
142

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection